Cellectar director granted 37,500 stock options

Cellectar Biosciences director Douglas J. Swirsky received a grant of stock options covering 37,500 shares of common stock at an exercise price of $2.70 per share.

Rhea-AI Filing Summary

Cellectar Biosciences director Douglas J. Swirsky received a grant of stock options covering 37,500 shares of common stock at an exercise price of $2.70 per share. The option vests in full on July 7, 2027, subject to his continued service, and expires on July 7, 2036. This is a compensation grant, with no open-market share purchases or sales reported.

Insider Trade Summary

Grant/Award: 37,500 shares

Grant/Award 1 txn

Insider Swirsky Douglas J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	37,500	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 37,500 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Option grant size: 37,500 options Exercise price: $2.70 per share Vesting date: July 7, 2027 +2 more

5 metrics

Option grant size 37,500 options Stock option award to director Douglas J. Swirsky

Exercise price $2.70 per share Exercise price of granted stock options

Vesting date July 7, 2027 Options vest in full on this date

Expiration date July 7, 2036 Options expire on this date

Derivative holdings after grant 37,500 options Total options held following this transaction

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, Exercise price, Vesting, +1 more

5 terms

Stock option (right to buy) financial

"Security title is listed as "Stock option (right to buy)"."

Grant, award, or other acquisition financial

"Transaction code description states "Grant, award, or other acquisition"."

Exercise price financial

"The conversion or exercise price is reported as 2.7000 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Vesting financial

"The option shall vest in full on July 7, 2027, subject to service."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Expiration date financial

"The option’s expiration date is disclosed as July 7, 2036."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cellectar Biosciences (CLRB) report for Douglas J. Swirsky?

Cellectar Biosciences reported that director Douglas J. Swirsky received a grant of stock options for 37,500 shares. These options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.

How many Cellectar Biosciences (CLRB) stock options were granted to Douglas J. Swirsky?

Douglas J. Swirsky was granted stock options covering 37,500 shares of Cellectar Biosciences common stock. This entire amount is reflected as his derivative holdings following the transaction, indicating a single new option award reported in this filing.

What is the exercise price of Douglas J. Swirsky’s Cellectar (CLRB) stock options?

The stock options granted to Douglas J. Swirsky have an exercise price of $2.70 per share. This means he can buy Cellectar common stock at $2.70 if he exercises the options after they vest and before they expire.

When do Douglas J. Swirsky’s Cellectar Biosciences (CLRB) options vest and expire?

The option grant to Douglas J. Swirsky vests in full on July 7, 2027, subject to his continued service. The options carry an expiration date of July 7, 2036, defining the final date on which they can be exercised.

Does the Cellectar Biosciences (CLRB) Form 4 show any stock being bought or sold on the market?

The Form 4 reports only a grant of stock options to Douglas J. Swirsky coded as a grant or award acquisition. It does not disclose any open-market purchases or sales of Cellectar common stock by him in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swirsky Douglas J

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.7	07/07/2026		A		37,500		(1)	07/07/2036	Common stock	37,500	$0	37,500	D

Explanation of Responses:

1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Chad Kolean, attorney-in-fact for Douglas Swirsky	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)